HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for early breast cancer: targeted drug may cut recurrence risk
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…
Matched conditions: HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a targeted pill keep High-Risk breast cancer at bay?
Disease control OngoingThis phase 3 trial studies whether adding the drug abemaciclib (Verzenios) to standard hormone therapy helps prevent breast cancer from coming back in 1,260 women with high-risk, HR+/HER2- early breast cancer. Participants have already completed initial treatments like surgery or…
Matched conditions: HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC